Green tea catechins and cardiovascular disease risk factors: Should a health claim be made by the United States Food and Drug Administration?

被引:14
|
作者
Murray, Morgan [1 ]
Walchuk, Chelsey [1 ]
Suh, Miyoung [1 ]
Jones, Peter J. [1 ]
机构
[1] Univ Manitoba, Richardson Ctr Funct Foods & Nutraceut, Dept Human Nutr Sci, Winnipeg, MB R3T 6C5, Canada
关键词
DOUBLE-BLIND; INSULIN-RESISTANCE; CONSUMPTION; EXTRACT; SUPPLEMENTATION; GLUCOSE; OBESE; CHOLESTEROL; TOXICITY; CANCER;
D O I
10.1016/j.tifs.2014.10.004
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Green tea (Camellia sinensis) is an ancient beverage stemming from China, more recently gaining interest in Western societies due to its antioxidant capacity. Cardiovascular disease (CVD), a disease of the heart and blood vessels, is a result of increased lipid concentrations and blood pressure, responsible for numerous deaths worldwide. Green tea is highly enriched in catechins, which may be responsible for its proposed CVD prevention mechanism. The objective of this paper was to examine the scientific evidence pertaining to green tea and CVD risk and evaluate whether enough credible scientific evidence exists to support a health claim by the United States Food and Drug Administration (US FDA). Sixteen clinical studies have examined the effects of green tea on CVD risk factors however, following a critical evaluation of these studies, a health claim cannot be recommended due to the safety and metabolites of green tea, as well due to lack of high quality and properly designed studies.
引用
收藏
页码:188 / 197
页数:10
相关论文
共 50 条
  • [41] A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Patel, Niti M.
    Stottlemyer, Britney A.
    Gray, Matthew P.
    Boyce, Richard D.
    Kane-Gill, Sandra L.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (02) : 309 - 322
  • [42] A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Niti M. Patel
    Britney A. Stottlemyer
    Matthew P. Gray
    Richard D. Boyce
    Sandra L. Kane-Gill
    Cardiovascular Drugs and Therapy, 2022, 36 : 309 - 322
  • [43] County Health Factors Associated with Avoidable Deaths from Cardiovascular Disease in the United States, 2006-2010
    Greer, Sophia
    Schieb, Linda J.
    Ritchey, Matthew
    George, Mary
    Casper, Michele
    PUBLIC HEALTH REPORTS, 2016, 131 (03) : 438 - 448
  • [44] Assessment of Cardiovascular Disease Risk Factors in a Genetically Homogenous Population of Parsi Zoroastrians in the United States: A Pilot Study
    Vazquez-Vidal, Itzel
    Chittoor, Geetha
    Laston, Sandra
    Puppala, Sobha
    Kayani, Zeeba
    Mody, Kaizeen
    Comuzzie, Anthony G.
    Cole, Shelley A.
    Voruganti, V. Saroja
    AMERICAN JOURNAL OF HUMAN BIOLOGY, 2016, 28 (03) : 440 - 443
  • [45] Ethnic variations in cardiovascular disease (CVD) risk factors and associations with prevalent CVD and CVD mortality in the United States
    Cheung, Queenie
    Wharton, Sean
    Josse, Andrea
    Kuk, Jennifer L.
    PLOS ONE, 2025, 20 (03):
  • [46] Trends in Cardiovascular Disease Risk Factors by Obesity Level in Adults in the United States, NHANES 1999-2010
    Saydah, Sharon
    Bullard, Kai McKeever
    Cheng, Yiling
    Ali, Mohammed K.
    Gregg, Edward W.
    Geiss, Linda
    Imperatore, Giuseppina
    OBESITY, 2014, 22 (08) : 1888 - 1895
  • [47] Risk factors for cardiovascular disease among Mexican-American adults in the United States and Mexico: a comparative study
    Morales, Leo S.
    Flores, Yvonne N.
    Leng, Mel
    Sportiche, Noemie
    Gallegos-Carrillo, Katia
    Salmeron, Jorge
    SALUD PUBLICA DE MEXICO, 2014, 56 (02): : 197 - 205
  • [48] Heterogeneity in cardio-metabolic risk factors and atherosclerotic cardiovascular disease among Asian groups in the United States
    Satish, Priyanka
    Sadaf, Murrium, I
    Valero-Elizondo, Javier
    Grandhi, Gowtham R.
    Yahya, Tamer
    Zawahir, Hassan
    Javed, Zulqarnain
    Mszar, Reed
    Hanif, Bashir
    Kalra, Ankur
    Virani, Salim
    Cainzos-Achirica, Miguel
    Nasir, Khurram
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 7
  • [49] Citizenship status and the prevalence, treatment, and control of cardiovascular disease risk factors in United States, 2011-2016
    Guadamuz, Jenny S.
    Durazo-Arvizu, Ramon
    Daviglus, Martha L.
    Calip, Gregory S.
    Nutescu, Edith A.
    Qato, Dima M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 159 - 160
  • [50] Greater prevalence of cardiovascular disease risk factors among persons with prehypertension, United States, 1999-2000.
    Greenlund, KJ
    Croft, JB
    Mensah, GA
    CIRCULATION, 2004, 109 (07) : E135 - E135